Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 4, 2015, Pages 567-573

  Sargentini, Valeria ^a   Ceccarelli, Giancarlo ^b   D'Alessandro, Mariadomenica ^a   Collepardo, Daniela ^a   Morelli, Andrea ^a   D'Egidio, Annalia ^b   Mariotti, Sabrina ^c   Nicoletti, Anna Maria ^a   Evangelista, Berta ^a   D'Ettorre, Gabriella ^b   Angeloni, Antonio ^b   Venditti, Mario ^b   Bachetoni, Alessandra ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

bacterial infection; critical care; presepsin; procalcitonin; sepsis monitoring; severe sepsis

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; PRESEPSIN; PROCALCITONIN; UNCLASSIFIED DRUG; CD14 ANTIGEN; PEPTIDE FRAGMENT; PRESEPSIN PROTEIN, HUMAN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT INFECTION; RELAPSE; SENSITIVITY AND SPECIFICITY; SEPSIS; BACTERIAL INFECTIONS; BLOOD; COHORT ANALYSIS; MIDDLE AGED; RECURRENT DISEASE;

BACTERIA (MICROORGANISMS);

ADULT; ANTIGENS, CD14; BACTERIAL INFECTIONS; BIOMARKERS; COHORT STUDIES; CRITICAL CARE; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECURRENCE;

EID: 84925803933     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0119     Document Type: Article

References (34)

1. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004;8:222-6.
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244-50.
3. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44.
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
5. Shapiro NI, Howell MD, Talmor D, Nathanson LA, Lisbon A, Wolfe RE, et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005;45:524-8.
6. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637-42.
7. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum pro-calcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17.
8. Haubitz S, Mueller B, Schuetz P. Streamlining antibiotic therapy with procalcitonin protocols: consensus and controversies. Expert Rev Respir Med 2013;7:145-57.
9. Herrmann W, Ecker D, Quast S, Klieden M, Rose S, Marzi I. Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients. Clin Chem Lab Med 2000;38:41-6.
10. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997;40:1250-6.
11. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000;343:1139-47.
12. Reinhart K, Meisner M, Brinkhorst FM. Markers for sepsis diagnosis: What is useful? Crit Care Clin 2006;22:503-19.
13. Tong HS, Liu YS, Wen Q, Tang YQ, Yuan FF, Su L. Serum procalci-tonin predicting mortality in exertional heatstroke. Emerg Med J 2012;29:113-7.
14. Hausfater P, Hurtado M, Pease S, Juillien G, Lvovschi VE, Salehabadi S, et al. Is procalcitonine a marker of critical illness in heatstroke? Intensive Care Med 2008;34: 1377-83.
15. Nylén ES, Al Arifi A, Becker KL, Snider RH Jr, Alzeer A. Effect of classic heatstroke on serum procalcitonin. Crit Care Med 1997;25:1362-5.
16. Balci C, Sivaci R, Akbulut G, Karabekir HS. Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. J Int Med Res 2009;37:1709-17.
17. Maier M, Wutzler S, Lehnert M, Szermutzky M, Wyen H, Bingold T, et al. Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma 2009;66: 243-9.
18. Mussap M, Degrandi R, Cataldi L, Fanos V, Plebani M. Biochemical markers for the early assessment of neonatal sepsis: the role of procalcitonin. J Chemother 2007;19(Suppl 2):35-8.
19. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013;50: 23-36.
20. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011;24(Suppl 2):12-4.
21. Mussap M, Puxeddu E, Burrai P, Noto A, Cibecchini F, Testa M, et al. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J Matern Fetal Neonatal Med 2012;25(Suppl 5):51-3.
22. Camussi G, Montrucchio G, Tobias PS. Lipopolysacchararide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol 1995;155:316-24.
23. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011;17:764-9.
24. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012;18: 891-7.
25. Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 2011;412:2157-61.
26. Bachetoni A, Mariani P, D'Alessandro M, Baiano V, Appodia C, Collepardo D, et al. Preliminary evaluation of the new TACR flex method versus MEIA method in the therapeutic monitoring of tacrolimus in organ transplantation. Transplant Proc 2007;39:2008-9.
27. ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for use of innovate therapies in sepsis. Crit Care Med 1992;20:867-74.
28. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physician/Society of Critical Care Medicine. Chest 1992;101:1644-55.
29. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
30. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
31. Rivers EP, Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin 2008; 24(3 Suppl):1-47.
32. Palmiere C, Mussap M, Bardy D, Cibecchini F, Mangin P. Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities. Int J Legal Med 2013;127:799-808.
33. Nakamura M, Takeuchi T, Naito K, Shirakawa K, Hosaka Y, Yama-saki F, et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. Crit Care 2008;12(Suppl 2):194.
34. Agilli M, Sener I, Yesildal F, Honca T, Aydin I, Akgul EO, et al. A new marker for the diagnosis of sepsis: presepsin. J Invest Biochem 2012;1:55-7.